The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on treatment for adults with major depressive disorder, the company said on Thursday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback